Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Fumaric acid esters prevent the NLRP3 inflammasome-mediated and ATP-triggered pyroptosis of differentiated THP-1 cells.
Episode 11 with Dr. Jack Antel on remyelination and on bedside-to-bench research
Is the MS community ready to promote brain health? Reception and Symposium
The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.
Classification of individuals based on ex-vivo glatiramer acetate-induced interferon-γ and interleukin-4 response.
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets.
Multiple sclerosis: Could Helicobacter pylori provide protection against multiple sclerosis?
10 years of interferon beta-1b (Beta feron therapy.
Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis.
Multiple Sclerosis: An Update.
Factors in Patient Empowerment: A Survey of an Online Patient Research Network.
In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity.
Immunology of Multiple Sclerosis.
Annual incidence, prevalence, and mortality of multiple sclerosis in white South-African-born and in white immigrants to South Africa.
[The overall assessment of the quality of the physical health of patients with multiple sclerosis after the application of physical therapy. Part 1].
Myelin injury induces axonal transport impairment but not AD-like pathology in the hippocampus of cuprizone-fed mice.
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients
Parenteral Treatment of Multiple Sclerosis: The Advent of Monoclonal Antibodies.
Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis.
New TECFIDERA® (dimethyl fumarate) data show sustained efficacy and long-term safety in a broad range of multiple sclerosis patients
The use of cytokine signature patterns: separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients.

Pages